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To the Editor:
The Journal of Thoracic Oncology
has published in its September 2007 issue
a meta-analysis about third-generation
agents in the treatment of advanced non-
small cell lung cancer.1 The authors have
considered the randomized trials pub-
lished until March 2004. Nineteen studies
were selected for the analysis. Some trials
published before 20042–8 were not in-
cluded without very obvious reasons. All
are European authors or publications in
European journals. Vinblastine has to be
considered as one of the active second-
generation drugs, the place of epirubicin
among those is more debatable. In addi-
tion, some important studies have been
published after 2004. It is not clear why
the authors have limited the literature re-
view to March 2004 to perform the meta-
analysis and to publish 3 years later with-
out updating the results.
In addition, a subgroup meta-analy-
sis of the trials comparing third-generation
doublets with second-generation triplets
would probably show no survival differ-
ence as suggested on Figure 5. Two
recently published studies9,10 might be
added to increase the power of the ag-
gregation, although carboplatin has been
used instead of cisplatin. This is an im-
portant question because those types of
triplets are still used in daily practice for
multiple reasons including cost.
Finally, overall survival rather
than 1-year survival should have been
considered, an end point fully possible
in literature-based meta-analyses.
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To the Editor:
We would like to thank Drs. Scu-
lier and Meert for their constructive
criticism of our recent meta-analysis
of third-generation agents in the treat-
ment of advanced non-small cell lung
cancer (NSCLC).1 Their comments re-
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flect the challenges of performing
meta-analyses. We developed these meta-
analyses to investigate commonly used
treatment paradigms within the United
States, and the trials were selected to
make the treatment comparisons as ho-
mogenous as possible. The decision to
use 1-year survival rate was based on the
fact that it is a recognized and accepted
end point for advanced stage trials. De-
termining the time period for inclusion
of trials is another significant challenge
since standard treatment practices may
change over time. By selecting trials that
were published before March 2004, we
selected for trials that completed en-
rollment before the widespread accep-
tance and implementation of second-
line therapies that had been proven to
extend survival. This assumption is
debatable, and a separate meta-analy-
sis with the inclusion of more recent
trials including the trials by Booton et
al.2 and Rudd et al.3 would be of sig-
nificant benefit.
We are also in agreement with the
authors that third-generation (3G) treat-
ments still have a significant role in the
treatment of advanced NSCLC. In fact, in
the primary analysis for the 1-year sur-
vival rate comparing 3G platinum-based
regimens versus second-generation (2G)
platinum-based regimens, we were unable
to come to a conclusion because of the
heterogeneity among the trials. The subset
analysis of the 2G doublets versus 3G
doublets was not one of the primary end
points of this meta-analysis, and was re-
quested by one of the reviewers. Our in-
tent in including this analysis was that it
may be hypothesis generating, and it is
deliberately included in the discussion
section rather than the results section.
In regards to the specific trials, the
trial by Martoni et al.4 was excluded
based on the investigator’s judgment
that cisplatin/epirubicin was not a com-
monly used therapy for NSCLC. The
trial by Comella et al.5 was excluded
because of the fact that epirubicin was
used in one treatment arm, and that ran-
domization was stopped early and 30
additional patients were enrolled on the
experimental arm. A second trial by Co-
mella et al.6 compared cisplatin and eto-
poside versus carboplatin, cisplatin, eto-
poside, and vinorelbine, thus, it could
not be classified into one of the treat-
ment comparisons of 2G versus 3G ther-
apies, and the use of two platinum
agents is currently not a common prac-
tice. The trial by Perol et al.7 included
patients with locally advanced NSCLC
who were treated with chemotherapy
followed by surgery or radiotherapy and
thus was excluded. The comparator arm
in trial by Danson et al.8 consisted of
two different chemotherapy treatments
and patients were not randomized be-
tween the two treatments, and thus the
trial was excluded. The trial by Sculier
et al.9 was excluded because of the fact
that it used a treatment combining both
cisplatin and carboplatin, which is not a
common practice.
The trial by Vansteenkiste et al.10
should have been included in the com-
parison of 3G monotherapy versus 2G
platinum-based regimens (n  871).
This trial compared treatment with gem-
citabine (n  84) versus cisplatin and
vindesine (n  85). The response rate
was 20% on both arms, and the 1-year
survival rates in the gemcitabine and
cisplatin/vindesine treatment arms were
22% and 19%, respectively. If a repeat
analysis (Figure 1) is performed with the
inclusion of this trial (n  1040), the
risk difference for response is 5%
(95% confidence interval, 10 to 0%;
p  0.075) and for 1-year survival rate
is 2% (95% confidence interval, 3 to
8%; p  0.40). This data continues to
suggest a higher response rate to 2G
platinum-based regimens relative to 3G
monotherapy, but equivalency in sur-
vival.
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FIGURE 1. Third-generation single agents compared with second-generation plat-
inum-based regimens. Differences in response and 1-year survival proportions.
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ERRATUM
In the article by Fukui T, Sakakura N, Mori S, et al, “Controversy about Small Peripheral Lung Adenocarcinomas: How
Should We Manage Them?”, J Thorac Oncol 2:546–552, 2007 the authors neglected to reference the publication by
Garfield DH, Cadranel JL, Wislez M, et al, The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum
of Disease, J Thorac Oncol 1:344–359, 2006 which was a valuable resource for their article. The authors regret this error.
Fukui T, Sakakura N, Mori S, et al. Controversy about Small Peripheral Lung Andenocarcinomas: How Should We Manage
Them? J Thorac Oncol. 2007;2:546–552.
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